Evidence map›Paper›PMID 18400964›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2008

A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.

Bruce Spinowitz, Michael Germain, Robert Benz, Marsha Wolfson, Tracy McGowan, K Linda Tang, Marc Kamin, Epoetin Alfa Extended Dosing Study Group

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2013
    Pooled it
  4. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2010
    Trial
  5. Trial
  6. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.Clinical journal of the American Society of Nephrology : CJASN · 2009
    Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Bruce SpinowitzNew York Hospital Queens, 56-45 Main Street, Flushing, NY 11355, USA. bss9001@nyp.org
Michael Germain
Robert Benz
Marsha Wolfson
Tracy McGowan
K Linda Tang
Marc Kamin
Epoetin Alfa Extended Dosing Study Group
New York Hospital Queens · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesAlthough epoetin alfa is commonly initiated weekly (QW) in anemic chronic kidney disease (CKD) patients, recent evidence indicates that it can be initiated every 2 wk (Q2W) and used in maintenance therapy every 4 wk (Q4W). This study examined the feasibility of initiating epoetin alfa Q4W in anemic CKD patients not receiving dialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This open-label study randomized subjects (1:2:2:2) to treatment with epoetin alfa 10,000 IU QW, 20,000 IU Q2W, 20,000 IU Q4W, or 40,000 IU Q4W for 16 wk. Subjects were > or =18 yr, had hemoglobin <11 g/dl, a glomerular filtration rate of 15 to 90 ml/min per 1.73 m(2), and had not received erythropoietic therapy within 8 wk. The primary analysis was a noninferiority comparison of the 40,000 IU Q4W to the 20,000 IU Q2W group in the per-protocol population with respect to hemoglobin change from baseline to the end of study.

resultsOf 262 subjects randomized, 229 comprised the per-protocol population. Mean hemoglobin change from baseline for the 40,000 IU Q4W group (1.24 g/dl) was not inferior to the 20,000 IU Q2W group (1.11 g/dl) with the lower limit of 95% CI, -0.21 g/dl. In the QW, 20,000 IU Q2W, 20,000 IU Q4W, and 40,000 IU Q4W groups, 90%, 87%, 75%, and 86% of subjects, respectively, achieved a hemoglobin increase > or =1 g/dl. Serious adverse events were similar across all groups.

conclusionsEpoetin alfa can be initiated Q4W in anemic CKD subjects.

Indexed as

AgedAged, 80 and overAnemiaChronic DiseaseDrug Administration ScheduleEpoetin AlfaErythrocyte TransfusionErythropoietinFeasibility StudiesFemaleFerritinsHematinicsHemoglobinsHumansInjections, SubcutaneousIron CompoundsEpoetin AlfaErythropoietinFerritinsHematinicsHemoglobinsIron CompoundsRecombinant ProteinsTransferrin

Identifiers

PMID18400964
PMCPMC2440274
OpenAlexW2139537558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.